Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care

Lead Research Organisation: University College London
Department Name: UNLISTED

Abstract

Our aim is to reduce cancer deaths and the side effects associated with cancer treatments. We design clinical trials and other research studies that test several new approaches at the same time. This speeds up the evaluation of new therapies.

Cancer is becoming more common, especially in low and middle income countries (LMICs) where it is estimated that 70% of cancers and 80% of cancer deaths will occur in 2020. We focus on the need for more affordable and effective cancer treatments. This is also important for high income countries.

We test drugs that are already used for another disease. This is called repurposing. We also test whether radiotherapy, surgery and existing scanning techniques can be used in different and more efficient ways to improve the diagnosis and treatment of cancer. We will also test whether newer drugs (immuno–oncology) can be given for shorter periods of time with the same benefits and less side effects.

In the future we will work on: a) cancers that are common and cause many deaths in LMICs; b) cancers that are less common which makes it difficult to run clinical trials; and c) studies to prevent cancer. Running a clinical trial in these areas can be challenging and not many research groups work in these areas.

The impact of our work is recognised if the treatments we assess are recommended for patients by doctors because of our trials. Further impacts are to help increase research visibility and capacity in LMICs, including for example heling to develop Principal Investigators in countries. We also collect biological samples from trial participants and scientists evaluate them to increase our understanding of cancer.

Technical Summary

Our aim is to improve cancer survival and decrease cancer morbidity by designing and implementing innovative late phase studies that have a major impact on clinical practice. We focus on adaptive trials that test more than one primary research hypothesis to increase efficiency including multi-arm multi-stage platforms, umbrella, and basket trial designs, primarily in the phase III setting.

Cancer incidence is increasing rapidly, and disproportionately so in low and middle income countries (LMICs) where it is estimated that 70% of cancers and 80% of cancer deaths will occur in 2020. This programme focusses on the need for affordable and less toxic therapies that can be implemented across a range of economic settings. We evaluate existing healthcare technologies (e.g. drug repurposing or rescheduling, established imaging techniques, surgery and radiotherapy) to optimise clinical efficacy and/or broaden the patient group that can benefit.

We address clinical questions others are unlikely to tackle, either due to a challenging clinical scenario, geographical setting, and/or lack of interest or support from the pharmaceutical industry. Consequently, and particularly in the future, we will focus on: a) cancers with a high incidence and mortality in LMICs; b) rarer and less common cancers; and c) prevention and early diagnosis as an affordable approach to improve outcomes. Integrated working with methodology colleagues enhances trial design, conduct and analysis, and facilitates the implementation of results.

Examples of drug repurposing projects include the evaluation of aspirin as an adjuvant therapy in common solid tumours and metformin as a potential anti-cancer therapy. Immuno-oncology projects are focussed on shorter and more affordable regimens and are underpinned by novel trial designs developed at the MRC CTU. Primary prevention cancer trials are long term projects; our aim is to conduct them efficiently, making optimal use of electronic health records.

We are developing an increasing network of investigators in LMICs - integral to this work is our capacity building activities in terms of education and mentorship in clinical research methodology, particularly in India. Impact is recognised by change in clinical practice and incorporation of the new clinical approach into international guidelines.

Maximising the potential between discovery science and applied research is key to our strategy with biological samples from trial participants analysed by cutting edge scientists and, where appropriate, results fed back into clinical practice and future trial designs. We are also building upon our trial work particularly in prostate cancer and our aspirin-related studies to establish repositories of trial data to facilitate meta-analyses.

Publications

10 25 50

Related Projects

Project Reference Relationship Related To Start End Award Value
MC_UU_00004/01 31/03/2021 30/03/2026 £5,186,000
MC_UU_00004/02 Transfer MC_UU_00004/01 31/03/2021 30/03/2026 £4,446,000
MC_UU_00004/03 Transfer MC_UU_00004/02 31/03/2021 30/03/2026 £4,999,000
MC_UU_00004/04 Transfer MC_UU_00004/03 31/03/2021 30/03/2026 £5,315,000
MC_UU_00004/05 Transfer MC_UU_00004/04 31/03/2021 30/03/2026 £3,107,000
MC_UU_00004/06 Transfer MC_UU_00004/05 31/03/2021 30/03/2026 £2,889,000
MC_UU_00004/07 Transfer MC_UU_00004/06 31/03/2021 30/03/2026 £2,369,000
MC_UU_00004/08 Transfer MC_UU_00004/07 31/03/2021 30/03/2026 £2,270,000
MC_UU_00004/09 Transfer MC_UU_00004/08 31/03/2021 30/03/2026 £2,160,000
 
Title Artwork based on the crystalline structure of acetyl-salicylic acid (aspirin) used for a participant thank you card. 
Description The Add-Aspirin team wished to express their thank you to the trial participants and collaborated to produce an artwork that was inspired by an image of the crystalline structure of acetyl-salicylic acid (aspirin). The final piece was painted by one of the team members (Aleksandra Gentry-Maharaj - Project Co-Lead) which reflected the input of the entire team. A photograph of the artwork was used on the front of the thank you card and featured colours from the Add-Aspirin logo. 
Type Of Art Artwork 
Year Produced 2023 
Impact These have now been sent to all sites to distribute to the trial participants. 
 
Guideline Title Covid Guidelines India
Description Anti-IL6 COVID-19 SR (PMID:34228774) CMGIG guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
Description Anti-IL6 COVID-19 SR (PMID:34228774) ERS guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title IDSA Guidelines on the Treatment and Management of Patients with COVID-19
Description Anti-IL6 COVID-19 SR (PMID:34228774) IDSA guideline 2022
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 (adults)
Description Anti-IL6 COVID-19 SR (PMID:34228774) NHS guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Description Associate PI webinar series
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic Bladder cancer
Description Bladder Adj CT IPD (PMID:15939530) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.3.2022 Bladder Cancer
Description Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.1.2024 Bladder Cancer
Description Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2024
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical Practice Guideline GU-013 Version 8 (Muscle Invasive Bladder Cancer) (2021)
Description Bladder Adj CT IPD (PMID:16625650) AHS guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic Bladder cancer
Description Bladder Adj CT IPD 2005 (PMID:15939530) EAU guideline 2023
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2022)
Description Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 3.2022
Description Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2024
Description Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2024
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical Practice Guideline GU-013 Version 8 (Muscle Invasive Bladder Cancer) (2023)
Description Bladder Neo CT IPD (PMID:15939524) AHS Guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022
Description Cervix CTRT IPD (PMID: 19001332) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2022 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2022 (1)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2023 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2023 (1)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1 2024 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2024 (1)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2022 Cervical Cancer
Description Cervix CTRT IPD (PMID:20091632) NCCN guideline 2022 (1)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2023 Cervical Cancer
Description Cervix CTRT IPD (PMID:20091632) NCCN guideline 2023 (1)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2024 Cervical Cancer
Description Cervix CTRT IPD (PMID:20091632) NCCN guideline 2024 (1)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022
Description Cervix CTRT SR (PMID: 16034873) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update
Description Cervix Neo CT IPD (PMID: 15106161) ASCO guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update
Description Cervix Neo CT SR (PMID:23235641) ASCO guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v2.2 2022
Description Cervix Neo CT SR (PMID:23235641) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Description Citation of RADICALS in APCCC 2023 Consensus Statement
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical reviews
Impact RCT results improve management of patient care
URL https://doi.org/10.1016/j.eururo.2022.11.002
 
Guideline Title EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer
Description Citation of RADICALS in EAU 2022 prostate cancer guidelines
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact Clinical trial should how improvements can be made to patient outcomes
URL https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelin...
 
Guideline Title EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer
Description Citation of STAMPDE in EAU 2022 prostate cancer guidelines
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact Clinical trial should how improvements can be made to patient outcomes
URL https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelin...
 
Description Citation of STAMPEDE in APCCC 2023 Consensus Statement
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical reviews
Impact RCT results improve management of patient care
URL https://doi.org/10.1016/j.eururo.2022.11.002
 
Guideline Title National Comprehensive Cancer Network (NCCN) Guidelines® Insights: Prostate Cancer, Version 1.2023: Featured Updates to the NCCN Guidelines
Description Citation of STAMPEDE in NCCN Guidelines Insights: Prostate Cancer, Version 1.2023
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact Clinical trials results improve patient outcomes
URL https://doi.org/10.6004/jnccn.2022.0063
 
Guideline Title Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer (from European Society for Medical Oncology (ESMO), Singapore Society of Oncology (SSO), China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS).
Description Citation of STAMPEDE in Pan-Asian adapted ESMO Prostate Cancer Guidelines
Geographic Reach Asia 
Policy Influence Type Citation in clinical guidelines
Impact RCTs results improve patient care
URL https://www.esmoopen.com/article/S2059-7029(22)00138-7/fulltext
 
Guideline Title S3-Leitlinie endometrriumkarzinom V2.0 (2022)
Description Endometrial CT SR (PMID: 22895938) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title S3-Leitlinie endometrriumkarzinom V3.01 (2023)
Description Endometrial CT SR (PMID: 22895938) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1 2024. Uterine Neoplasms
Description Endometrial CT SR (PMID:17150999) NCCN guideline 2024 (V1)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer
Description Lung Adj CT IPD (PMID:20338628) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2024. Non-Small Cell Lung Cancer
Description Lung Adj CT IPD (PMID:20338628) NCCN guideline 2024
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Description Lung Adj CT IPD (PMID:25730344) ASCO guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Description Lung CT 95 IPD (PMID:7580546) ASCO guideline stage I-III NSCLC 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative
Description Lung CT 95 IPD (PMID:7580546) CSCO-ESMO guideline 2018
Geographic Reach Asia 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Lung CT 95 IPD (PMID:7580546) NCCN guideline 2023
Description Lung CT 95 IPD (PMID:7580546) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022)
Description Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023)
Description Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer
Description Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022)
Description Lung PORT IPD (PMID: 9690404) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023)
Description Lung PORT IPD (PMID: 9690404) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer
Description Lung PORT IPD (PMID: 9690404) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2024. Non-Small Cell Lung Cancer
Description Lung PORT IPD (PMID: 9690404) NCCN guideline 2024
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Description Lung PORT IPD (PMID: 9690404; 23453644) ASCO guideline 2022
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022)
Description Lung SC IPD (PMID: 18678835) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2024)
Description Lung SC IPD (PMID: 18678835) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1.2023. Non-Small Cell Lung Cancer
Description Lung SC IPD (PMID: 18678835) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022)
Description Lung SC IPD (PMID: 25730344) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023)
Description Lung SC IPD (PMID: 25730344) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative
Description Lung SC IPD (PMID:18678835) CSCO-ESMO guideline 2018
Geographic Reach Asia 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V2.1 (2022)
Description Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. V3.01 (2023)
Description Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v1.2023. Non-Small Cell Lung Cancer
Description Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v2.2024. Non-Small Cell Lung Cancer
Description Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2024
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. V3.1 (2022)
Description Oesophagus RT IPD (PMID:16235286) GGPO guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. V4.0 (2023)
Description Oesophagus RT IPD (PMID:16235286) GGPO guideline 2023
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Guidelines Version 5.2022 Esophageal and Esophagogastric Junction Cancers
Description Oesophagus RT IPD (PMID:9635705) NCCN guideline 2022 (v5)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Guidelines Version 4.2023 Esophageal and Esophagogastric Junction Cancers
Description Oesophagus RT IPD (PMID:9635705) NCCN guideline 2023 (v4)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2019)
Description Prostate Abi AD (PMID: 28800492) EAU guideline 2019
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2021)
Description Prostate Abi AD (PMID: 28800492) EAU guideline 2021
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2022)
Description Prostate Abi AD (PMID: 28800492) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2023)
Description Prostate Abi AD (PMID: 28800492) EAU guideline 2023
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Local Prostate Cancer
Description Prostate Artistic AD (PMID: 33002431) AHS guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022)
Description Prostate Artistic AD (PMID: 33002431) AUA/ASTRO guideline 2022
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2022)
Description Prostate Artistic AD (PMID: 33002431) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2023)
Description Prostate Artistic AD (PMID: 33002431) EAU guideline 2023
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer
Description Prostate Artistic AD (PMID: 33002431) NCCN guideline 2023 V1
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.4.2023 Prostate Cancer
Description Prostate Artistic AD (PMID: 33002431) NCCN guideline 2023 V4
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Pan-Asian adapted ESMO Guidelines (2022)
Description Prostate Artistic AD (PMID: 33002431) PAGA ESMO guideline 2022
Geographic Reach Asia 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2022)
Description Prostate CT SR (PMID: 26718929) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2023)
Description Prostate CT SR (PMID: 26718929) EAU guideline 2023
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Pan-Asian adapted ESMO Guidelines (2022)
Description Prostate CT SR (PMID: 26718929) PAGA ESMO guideline 2022
Geographic Reach Asia 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2023 Prostate Cancer
Description Prostate CT SR (PMID: 30826218) NCCN guideline 2023
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.4.2023 Prostate Cancer
Description Prostate CT SR (PMID: 30826218) NCCN guideline 2023 v4
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2022)
Description Prostate Network AD (PMID: 29788164) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer
Description Prostate RT AD (PMID: 30826218) CUA guideline 2022
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2022)
Description Prostate RT AD (PMID: 30826218) EAU guideline 2022
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guideline: Prostate Cancer (2023)
Description Prostate RT AD (PMID: 30826218) EAU guideline 2023
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v3.2023 Soft Tissue Sarcoma
Description Sarcoma CT IPD (PMID:9400508) NCCN guideline 2023 (V3)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.2.2022 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2022 (V2)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.3.2023 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2023 (V3)
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Description CRUK/06/001: PATCH: Prostate Adenocarcinoma: TransCutaneous Hormones - 2021 extension
Amount ÂŁ592,034 (GBP)
Funding ID C471/A12443 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2021 
End 09/2024
 
Description RADICALS extension (A7829/A6381)
Amount ÂŁ325,000 (GBP)
Funding ID (A7829/A6381) 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2020 
End 03/2023
 
Description REFINE stage I/II funding, Jon Moulton
Amount ÂŁ1,061,788 (GBP)
Organisation J P Moulton Charitable Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2020 
End 04/2024
 
Description Research Careers Committee - Clinical Trial Fellowship - November 2021 - Dr Sophie Merrick
Amount ÂŁ150,581 (GBP)
Funding ID RCCCTF-Nov21\100002 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 12/2025
 
Title PATCH trial sample storage 
Description In PATCH, blood and urine samples were collected at randomisation and various time points during trial follow-up for consenting patients randomised up to end October 2013. Baseline blood samples for future research are also being collected in all consenting patients (before and after October 2013). Until September 2021, all samples were stored at Charing Cross Hospital Assay Laboratory. In September 2021, samples were transferred to the Biodock biobank in Nottingham. 
Type Of Material Biological samples 
Year Produced 2006 
Provided To Others? No  
Impact These samples will be utilised in analyses to increase understanding of the underlying mechanisms for the potential benefits and adverse effects of the trial treatments, for example, for assessing changes in SHBG, oestrone/oestradiol ratio and bone biomarkers during time on treatment. 
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Antwerp University Hospital
Country Belgium 
Sector Hospitals 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Cantonal Hospital St. Gallen
Country Switzerland 
Sector Hospitals 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Leiden University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation National Cancer Centre Singapore
Country Singapore 
Sector Hospitals 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Oslo University Hospital
Country Norway 
Sector Hospitals 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Saitama Medical University
Country Japan 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Swiss Group for Cancer Clinical Research (SAKK)
Country Switzerland 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation Tata Memorial Hospital
Country India 
Sector Hospitals 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation University of Bern
Country Switzerland 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Aspirin after radical therapy for colorectal cancer: a prospective meta-analysis 
Organisation University of Sydney
Department NHMRC Clinical Trials Centre
Country Australia 
Sector Academic/University 
PI Contribution Conception; First drafts of protocol; Protocol finalisation and submission
Collaborator Contribution Commenting on protocol
Impact Protocol: PROSPERO CRD42023453156
Start Year 2021
 
Description Collaboration with Professor Sir John Burn and his team at Newcastle University 
Organisation Newcastle University
Country United Kingdom 
Sector Academic/University 
PI Contribution This collaboration builds on the work of AsCaP where both UCL and Newcastle University are two of the partners. The planned work focusses on profiling the Add-Aspirin colorectal cohort for PIK3CA, KRAS, BRAF mutations and MMRd status. The plan is to profile the entire colorectal cohort using material derived from the tissue blocks collected as part of the trial. Ethical approval for the study has been received and the first batch of colorectal tumour samples have been sent to the Newcastle lab.
Collaborator Contribution Newcastle University has unique expertise in profiling tumours, especially for these mutations.
Impact Not as yet.
Start Year 2022
 
Description REFINE translational samples - storage and analysis (NIH) 
Organisation National Institutes of Health (NIH)
Department National Cancer Institute (NCI)
Country United States 
Sector Public 
PI Contribution Within REFINE, blood samples are taken prior to each treatment administration. The aims are to better understand both the pharmacokinetics of immune checkpoint inhibitors and also the pharmacodynamics with respect to target efficacy between different frequencies of administration. These samples will initially be stored at Imperial College in the UK, before being transferred to Dr Cody Peer and Dr William Figg at the National Cancer Institute for analysis.
Collaborator Contribution The expertise of the NIH, and in particular Drs Peer and Figg, is key to the analysis of the trial samples, and the interpretation of the results.
Impact REFINE is in the final stages of set-up, so no outputs yet.
Start Year 2022
 
Description Training the next generation of Indian clinical trialists 
Organisation Christian Medical College, Vellore
Country India 
Sector Academic/University 
PI Contribution Have provided guidance, contributed to each aspect of the development of an Indian MSc (details below), visitied both Indian sites and taught on the MSc
Collaborator Contribution Worked together to develop and deliver an Indian MSc - details below Submitted a BC grant application to support exchanges of students and staff which was successful
Impact Secured funding from British Council - Going Global Partnerships India - Collaborative Grant Launch in Sept 2022 a two-year MSc in Clinical Research with specialisation in Clinical Trials at THSTI, India. Twelve students have been enrolled in 2022 and a second batch of 12 in 2023.. The degree will be awarded by RCB India. Multidisciplinary - clinicians, statisticians, clinical trialists
Start Year 2019
 
Description Training the next generation of Indian clinical trialists 
Organisation Translational Health Science And Technology Institute
Country India 
Sector Public 
PI Contribution Have provided guidance, contributed to each aspect of the development of an Indian MSc (details below), visitied both Indian sites and taught on the MSc
Collaborator Contribution Worked together to develop and deliver an Indian MSc - details below Submitted a BC grant application to support exchanges of students and staff which was successful
Impact Secured funding from British Council - Going Global Partnerships India - Collaborative Grant Launch in Sept 2022 a two-year MSc in Clinical Research with specialisation in Clinical Trials at THSTI, India. Twelve students have been enrolled in 2022 and a second batch of 12 in 2023.. The degree will be awarded by RCB India. Multidisciplinary - clinicians, statisticians, clinical trialists
Start Year 2019
 
Description A talk or presentation - Ruth Langley provided an update on Add-Aspirin and the translational research resulting from the trial at the final meeting of the AsCaP consortium including all international partners. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Ruth Langley provided an update on Add-Aspirin and the translational research resulting from the trial at the AsCaP final meeting of all international partners on 12 February 2024 in London, UK.
Year(s) Of Engagement Activity 2024
 
Description Associate PI training webinar series 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Webinar series for members of NIHR Associate PI scheme (initially an idea within REFINE, then to all CTU trials, then expanded to include all members of the scheme nationwide). Approximately monthly hour long online seminars covering various aspects of clinical trials, so far including safety reporting, sample size calculations, trial design, health economics, recruiting to challenging trials, how to be a good PI, etc. Sessions have been attended by up to 150 people, with a potential audience of >1000 on the API scheme at any one time.
Year(s) Of Engagement Activity 2022,2023,2024
 
Description ESGO 2023: ICON8B Progression Free Survival Results 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact International conference to present primary Progression Free Survival results for ICON8B
Year(s) Of Engagement Activity 2023
URL https://ijgc.bmj.com/content/33/Suppl_3/A424
 
Description Engagement with Add-Aspirin PPI representatives 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact A virtual meeting was held with 6 Add-Aspirin PPI representatives (representing all disease cohorts) on 13 April 2023 to update them on the progress of the trial, gain their views on current issues and boost engagement. The next meeting is planned 25 March 2024 and further regular meetings are planned.
Year(s) Of Engagement Activity 2023
 
Description European Society of Medical Oncology Congress Abstract - Reducing the Frequency of Immune Checkpoint Inhibition in Cancer 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A trials in progress abstract was presented 'REducing the Frequency of ImmuNE checkpoint inhibition in cancer' at the European Society of Medical Oncology Congress in September 2023 in Paris.
Year(s) Of Engagement Activity 2022
URL https://oncologypro.esmo.org/meeting-resources/esmo-congress/reduced-frequency-immune-checkpoint-inh...
 
Description Focus Groups with people affected by melanoma and renal cell carcinoma 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact A series of focus groups were conducted with people affected by kidney cancer and melanoma in order to understand patient perspectives of reducing the intensity of immune checkpoint inhibition.
Year(s) Of Engagement Activity 2023
URL https://www.mrcctu.ucl.ac.uk/studies/all-studies/r/refine/optic
 
Description MRC Clinical Trials Unit (MRC CTU) at UCL Capacity Strengthening Hub on the Global Health Network 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This Hub aims to provide resources on the design, conduct, analysis, and knowledge transfer and exchange for randomised controlled trials, observational studies, and meta-analyses. We will also advertise new training opportunities and short courses. The resources shared on the Hub have been created by the MRC CTU at UCL and partners, some are for particular trials and studies and others are more generic.
The Hub includes essential readings lists. We have also run a series of webinars, attracting hundreds of participants. We have recently launched a mentoring scheme.
Year(s) Of Engagement Activity 2023,2024
URL https://mrcctu.tghn.org/
 
Description Podcast episode: The REFINE trial: how can we improve the way we give cancer immunotherapy? 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact In this episode, Clinical Fellow Sophie Merrick discusses how the REFINE trial hopes to address this problem, by testing if giving immunotherapy less frequently can still treat the cancer effectively, whilst improving the quality of life for patients, reducing side effects and costs.
Year(s) Of Engagement Activity 2023
URL https://soundcloud.com/trial-talk-podcast/the-refine-trial
 
Description Poster at Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster presented at conference - Exploring the disparity between mortality reduction and stage shift, treatment and survival from randomisation in High Grade Serous Ovarian Cancer in UKCTOCS
Year(s) Of Engagement Activity 2019
 
Description Presentation on RADICALS for Prostate Cancer Support Organisation (PCaSO) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Online presentation by Chris Parker (Chief Investigator) on RADICALS trials results for Prostate Cancer Support Organisation (PCaSO)
Year(s) Of Engagement Activity 2023
URL https://pcaso.org/zoom-event-2nd-march-on-radicals-hd/
 
Description Ruth Langley provided an update on Add-Aspirin and the translational research resulting from the trial at the AsCaP annual meeting of all international partners. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Ruth Langley provided an update on Add-Aspirin and the translational research resulting from the trial at the AsCaP annual meeting of all international partners on 15-16 May 2023 in Paris, France.
Year(s) Of Engagement Activity 2023
 
Description STAMPEDE M1RT infographic 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This infographic summarises results from the M1RT comparison of the STAMPEDE trial.
Year(s) Of Engagement Activity 2022
URL https://www.mrcctu.ucl.ac.uk/media/2108/full-infographic_stampede-m1-radiotherapy-comparison.png
 
Description STAMPEDE docetaxel M0 long-term follow-up infographic 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This infographic summarises long-term results from the docetaxel comparison of the STAMPEDE trial.
Year(s) Of Engagement Activity 2022
URL https://www.mrcctu.ucl.ac.uk/media/2147/infographic-stampede-docetaxel_2.png
 
Description TRISST Health Economics 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation of TRISST Health Economics at GU ASCO 2023
Year(s) Of Engagement Activity 2023
URL https://meetings.asco.org/abstracts-presentations/217707
 
Description TRISST infographic 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This infographic summarises key results from the TRISST trial.
Year(s) Of Engagement Activity 2022
URL https://www.mrcctu.ucl.ac.uk/media/2065/trisst_infographic_final_v2.png
 
Description Talk given to Add-Aspirin Gastro-Oesophageal cohort investigators with national participation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The gastro-oesophageal (GO) cohort is the final recruiting cohort in the Add-Aspirin trial. The Add-Aspirin core team organised calls with the GO investigators to discuss recruitment, provide support, boost engagement and discuss any other trial updates with national site teams. Calls have been held on 11 July 2023, 31 October 2023, 08 February 2024.
Year(s) Of Engagement Activity 2023,2024
 
Description Thee episodes of Immunobuddies podcast discussing REFINE trial 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Sophie Merrick appeared on three episodes of the Immunobuddies podcast to discuss immunotherapy treatment and specifically the REFINE trial.
Year(s) Of Engagement Activity 2024
URL https://www.buzzsprout.com/2128662
 
Description UCL MSc Clinical Trials Programme - teaching on trial background and design using the Add-Aspirin example 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Add-Aspirin co-Project Lead outlined the Add-Aspirin trial background and design to provide insights to MSc Clinical Trials students
Year(s) Of Engagement Activity 2023